April 6, 2004

20/20 Receives a $79,501 Phase I SBIR Award to Develop a Clinical Diagnostic Tool for Profiling Patients with Kidney Cancer from the National Cancer Institute (ROCKVILLE) – 20/20 GeneSystems, Inc. received $79,501 from the National Cancer Institute through their SBIR program to develop a clinical diagnostic tool for profiling the EGFR signaling pathway in tumors from patients with kidney cancer. The diagnostic tool would be used to predict the subset of patients most likely to respond to targeted EGFR inhibitor therapies based on tumor profiles. Therefore, the efficacy of these targeted therapies in kidney cancer patients could be greatly increased.